Health Care & Life Sciences » Biotechnology | Momenta Pharmaceuticals Inc.

Momenta Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
35,465.00
52,250.00
89,650.00
109,619.00
138,882.00
75,589
SG&A Expense
136,887.00
142,948.00
165,429.00
175,224.00
206,757.00
198,039
EBIT
109,591.00
99,396.00
84,434.00
74,727.00
77,051.00
163,520
Unusual Expense
-
-
-
51,200.00
15,500.00
17,807
Non Operating Income/Expense
233.00
248.00
313.00
298.00
28.00
928
Pretax Income
108,408.00
98,600.00
83,313.00
21,003.00
88,096.00
176,061
Consolidated Net Income
108,408.00
98,600.00
83,313.00
21,003.00
88,096.00
176,061
Net Income
108,408.00
98,600.00
83,313.00
21,003.00
88,096.00
176,061
Net Income After Extraordinaries
108,408.00
98,600.00
83,313.00
21,003.00
88,096.00
176,061
Net Income Available to Common
108,408.00
98,600.00
83,313.00
21,003.00
88,096.00
176,061
EPS (Basic)
2.13
1.91
1.32
0.31
1.20
2.26
Basic Shares Outstanding
50,907.00
51,664.00
63,130.00
68,656.00
73,136.00
77,845
EPS (Diluted)
2.13
1.91
1.32
0.31
1.20
2.26
Diluted Shares Outstanding
50,907.00
51,664.00
63,130.00
68,656.00
73,136.00
77,845
EBITDA
101,422.00
90,698.00
75,779.00
65,605.00
67,875.00
152,450
Non-Operating Interest Income
950.00
548.00
808.00
2,226.00
4,427.00
6,194

About Momenta Pharmaceuticals

View Profile
Address
301 Binney Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.momentapharma.com
Updated 07/08/2019
Momenta Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products. It focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune disease. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.